TW202131943A - Use of preparing pharmaceutical composition for external use to treat itching or allergic symptoms and preparation method of pharmaceutical composition for external use capable of producing the functions of anti-inflammation and skin repair - Google Patents

Abstract

The present invention discloses a use of preparing pharmaceutical composition for external use to treat itching or allergic symptoms, which is characterized in that: the pharmaceutical composition for external use includes smilax glabra, schizonepetae herba, saposhnikovia divaricata, kochia scoparia, dictamnus dasycarpus, phellodendron chinense, ligusticum chuanxiong, angelica sinensis, polygonum multiflorum, angelica dahurica, baibu, sophora flavescens, bletilla striata and evening primrose oil. In this way, with the pharmaceutical composition for external use with the aforementioned ingredients, it is able to produce functions of anti-inflammation, blood invigoration and nourishment, and skin repairs after being applied to the wound or the place where the disease occurs.

Description

Use of preparing external pharmaceutical composition to treat itching or allergic symptoms and preparation method of external pharmaceutical composition

The invention belongs to the field of medicines, and in particular is a medicinal composition that is applied to the skin to treat itching or allergic symptoms and a preparation method thereof.

According to statistics, uremic pruritus (uremic pruritus) is a common and distressing symptom in patients with end-stage renal disease (ESRD). Its pathophysiology has not been fully understood, and although the symptoms can be relieved after treatment, it is very difficult to eradicate. The prevalence rate of uremia pruritus in adult dialysis patients varies considerably from year to year. Some studies suggest that the increase in dialysis efficiency may reduce the prevalence rate to explain its prevalence rate from 50 and 90% in 1980 and 1993 to follow-up studies. The report shows 22~57%; another large study (the Dialysis Outcomes and Practice Patterns Study [DOPPS]) shows that the prevalence rate of uremia in adult dialysis patients is 42%.

Uremia pruritus is most commonly found on the back, but arms, head and abdomen may also occur. There are also many patients with systemic pruritus. The frequency of occurrence ranges from a few minutes a day to almost uninterrupted persistent pruritus and allergies. Wait. Common features include deterioration at night, which affects the quality of sleep. This condition occurs in patients with more severe uremia and scrapie, and can even make the patient tired and depressed; and high temperature (especially in the case of a lot of sweating) and Stress can also aggravate the symptoms of itching. In addition, some patients experience increased itching during dialysis, while others are lessened.

In addition, patients with uremic pruritus are prone to dry skin, scaly appearance or epidermal cracking, because repeated scratching produces significant skin changes, such as epidermal exfoliation (excoriations), simple lichen simplex (lichen simplex), nodularity Pruritus nodularis, keratotic papules, follicular hyperkeratosis and Acquired perforating dermatosis (APD).

Because the symptoms of itching are very common in dialysis patients, unless there is consistent and convincing evidence that the patient's itching is due to other causes, clinically, it will be assumed that the patient's itching is from uremic itching. The characteristics that can be referred to in clinical diagnosis include: the occurrence of itching at the beginning of dialysis, the continuous uninterrupted symptoms, and the significant increase in the concentration of calcium, phosphorus and magnesium ions, parathyroid hormone, and serum urea nitrogen.

In addition, since the pathophysiology of uremia pruritus has not been fully studied, the most effective treatment is still not available. For patients with severe pruritus, even though the optimal Kt/V target is reached, pruritus is still not available. improve. Uremia and pruritus are treated with oral antihistamines and gabapentin, topical emollients or local analgesics, ultraviolet B (UVB) phototherapy, and kidney transplantation. However, there are many patients with intractable uremia and pruritus in the clinic, after receiving the above treatment methods, there is no significant effect, and it is not easy to wait for a kidney transplant. At present, the more widely used external treatment methods for the treatment of uremia and itching are as follows: 1. Emollients (emollients) are the first choice for topical treatment of uremia and itching, and it is more recommended for patients with symptoms of sjogren on physical examination. 2. Local analgesics (such as pramoxine) can relieve itching. In a randomized trial sponsored by a pharmaceutical company, which included 28 hemodialysis patients, comparing the use of pramoxine twice a day with the emollient alone, it was found that patients who used pramoxine improved significantly (61 and 12%, respectively). Pramoxine proved to be safe and convenient in this trial. It is recommended for patients who have been using emollients regularly and still have persistent itching. 3. Essential oils to increase the water content of the stratum corneum. In a 2-week, randomized, placebo-controlled study, patients were divided into two groups, one group was treated with 2.2% linoleic acid (γ-lynolenic acid) cream three times a day, and the other group was treated with placebo The cream was used three times a day, and it was found that the use of sublinoleic acid cream was more effective in reducing the symptoms of itching than the placebo group.

However, there are still many patients who use the above-mentioned external treatments of Western medicine to improve the itching situation for a while, but the intensity of itching can not be better controlled for a long time, and the above-mentioned treatment methods cannot effectively repair the existing skin. Wounds cause slow wound repair, and at the same time, itching makes it more difficult to heal wounds. Therefore, whether the treatment is different from traditional Western medicine has become a goal that the medical community needs to think about and study.

In view of this, the inventor feels that he is not perfect and exhausts his mental and painstaking research, and based on his accumulated experience in this industry for many years, he provides a pharmaceutical composition for external use to treat itching or allergic symptoms and external medicine. The preparation method of the composition is expected to improve the deficiency of the above-mentioned conventional technology.

One purpose of the present invention is to provide a method for preparing a pharmaceutical composition for external use to treat itching or allergic symptoms and a method for preparing the pharmaceutical composition for external use, which is made into a pharmaceutical composition for external use with pure natural Chinese herbal ingredients to achieve moisturizing and antipruritic , Can also help wound repair.

Therefore, the present invention discloses a use for preparing a pharmaceutical composition for external use to treat itching or allergic symptoms, which is characterized in that the pharmaceutical composition for external use has Smilax glabra, Nepeta, Parsnip, Kochia scoparia, white fresh bark, Phellodendron chinense, Ligusticum chuanxiong, Angelica, Polygonum multiflorum, Angelica dahurica, Baibu, Sophora flavescens, Bletilla striata and evening primrose oil.

Preferably, Smilax glabra is 13 parts by weight, Nepeta is 10 parts by weight, Parsnip is 5 parts by weight, Kochia scoparia is 5 parts by weight, Baixian peel is 5 parts by weight, Phellodendron It is 5 parts by weight, Ligusticum chuanxiong is 5 parts by weight, Angelica is 5 parts by weight, Polygonum is 5 parts by weight, Angelica dahurica is 5 parts by weight, Stemone is 5 parts by weight, Sophora flavescens The line is 5 parts by weight, and the Bletilla line is 5 parts by weight.

Preferably, the application mode of the external pharmaceutical composition is selected from one or a combination of the following groups: essential oils, emulsions, creams, solutions, suspensions or ointments.

Preferably, itching or allergic symptoms refer to the hair follicles caused by uremic pruritus (excoriations), lichen simplex (lichen simplex), pruritus nodularis (pruritus nodularis), and keratotic papules (keratotic papules). Follicular hyperkeratosis (follicular hyperkeratosis) and Acquired perforating dermatosis (APD) or onychomycosis.

In addition, the present invention also discloses a method for preparing a pharmaceutical composition for external use for treating itching or allergic symptoms. The method comprises the following steps: taking 13 parts by weight of Smilax glabra, 10 parts by weight of Nepeta, 5 parts by weight of parsnip, 5 parts by weight of Kochia scoparia, 5 parts by weight of white fresh peel, 5 parts by weight of cork, 5 parts by weight of Ligusticum chuanxiong, 5 parts by weight of Angelica, 5 parts by weight of Polygonum multiflorum, 5 parts by weight Angelica dahurica, 5 parts by weight of Stemona, 5 parts by weight of Sophora flavescens, and 5 parts by weight of Bletilla; Add the above ingredients into evening primrose oil, heat and boil at 90~100 degrees for 2 hours; and after oil extraction After filtering impurities, the external pharmaceutical composition can be obtained.

In some embodiments, the external pharmaceutical composition is formed by adding 300 grams of refined shea butter and 140 grams of refined beeswax to form the external pharmaceutical composition in an ointment form.

In some embodiments, the pharmaceutical composition for external use is further added with refined shea butter and olive emulsifying wax, and the weight ratio of refined shea butter to olive emulsifying wax is 15 to 4. The composition is heated to melt before adding Pure water, and the volume ratio of the external pharmaceutical composition to pure water is 10 to 31, and continuous stirring can form the cream-type external pharmaceutical composition.

In some embodiments, the pharmaceutical composition for external use is further added with refined shea butter and olive emulsified wax, and the weight ratio of refined shea butter to olive emulsified wax is 5 to 2, which is heated to melt before adding Pure water, and the volume ratio of the external pharmaceutical composition to pure water is 5 to 19, and the external pharmaceutical composition of the emulsion type can be formed by continuous stirring.

Preferably, the volume of evening primrose oil added is 1100 ml.

In this way, through the above-mentioned preparation method and the prepared external pharmaceutical composition, after being applied to the wound or the place where the disease occurs, it can produce anti-inflammatory, invigorating blood and nourishing, and repairing skin effects. The medicinal composition composed of pure natural Kampo herbs can stay on the wound or itching for a longer time, which is more conducive to the repair of the wound and the improvement of anti-itching effect. At the same time, due to the relationship of natural herbs, it can stay on the wound for a long time. It will not cause other undesirable changes to the skin, such as allergies. Compared with the traditional western medicine compound, the treatment method is much milder, indicating the practicality and innovation of the present invention.

In order to enable those with ordinary knowledge in the field to clearly understand the content of the present invention, please refer to the following description and drawings.

The following are different examples to show the actual effect of the external pharmaceutical composition provided by the present invention, and the external pharmaceutical composition of the present invention has Smilax chinensis, Nepeta, Parsnip, Kochia scoparia, fresh bark, Phellodendron amurense , Ligusticum chuanxiong, Angelica, Polygonum multiflorum, Angelica dahurica, Stemone, Sophora flavescens, and Bletilla striata, and the preparation method of the topical pharmaceutical composition used in these examples is to take 13 parts by weight of Smilax glabra and 10 parts by weight of Nepeta , 5 parts by weight of parsnip, 5 parts by weight of Kochia scoparia, 5 parts by weight of white fresh peel, 5 parts by weight of cork, 5 parts by weight of Ligusticum chuanxiong, 5 parts by weight of Angelica, 5 parts by weight Parts of Polygonum multiflorum, 5 parts by weight of Angelica dahurica, 5 parts by weight of Stemona, 5 parts by weight of Sophora flavescens, and 5 parts by weight of Bletilla striata, and after adding the above ingredients to 1100 ml of top evening primrose oil, it is maintained after heating and boiling Boil at 90 to 100 degrees for 2 hours, then extract the oil and filter impurities to obtain the pharmaceutical composition for external use. At this time, the pharmaceutical composition for external use is presented in the form of essential oils. In these examples, it is in the form of ointment. Therefore, the topical pharmaceutical composition of essential oil type will be processed again, that is, the topical pharmaceutical composition will be shaped by adding 300 grams of pure natural refined shea butter and 140 grams of pure natural refined beeswax. The external pharmaceutical composition is formed into a paste, and an appropriate amount is applied to the affected area according to the condition of the patient.

In addition, the pharmaceutical composition for external use can also be presented in the form of emulsion, cream, solution or suspension, and the method for the pharmaceutical composition for external use of the cream type is to add refined shea butter and olive to the pharmaceutical composition for external use. Emulsified wax, and the weight ratio of refined shea butter and olive emulsified wax is 15 to 4. After heating to melt, add pure water, and the volume ratio of the external pharmaceutical composition to pure water is 10 to 31, continuing The external pharmaceutical composition of cream type can be formed by stirring. The method for the external pharmaceutical composition of the emulsion type is to add refined shea butter and olive emulsifying wax to the external pharmaceutical composition, and the weight ratio of refined shea butter to olive emulsifying wax is 5 to 2, heating After melting, pure water is added, and the volume ratio of the external pharmaceutical composition to pure water is 5 to 19, and the external pharmaceutical composition of the emulsion type can be formed by continuous stirring.

The first embodiment

Please refer to Figures 1 and 2, which are schematic diagrams of the itching scale before and after treatment and diagrams of the improvement of skin lesions before and after treatment according to the first embodiment of the present invention. As shown in the figure, the patient in this example has been on hemodialysis for 10 years, has itchy for 9 years, often scratches until bleeding, the clothes on his body are always bloody, and his body is covered with uremic acne and scratches, as shown in Figure 2. According to 20181121, scratching and insomnia in the middle of the night also affected the person next to the pillow. In the past 9 years, I have sought medical treatment and tried a variety of treatments to no avail. When Mr. Xiao came to the doctor for the first time, he was evaluated by the Itching Scale. As shown in 20181017 on the left side of the first figure, it belongs to a very serious level. After receiving the application of the pharmaceutical composition for external use, the degree of itching was greatly reduced, and the quality of sleep was also greatly improved, as shown by the continuous downward movement of the curve in the first figure, the skin wound improved and closed, as shown in the second figure. As shown in the comparison of the photos of the two groups of 20181121 and 20190419, it can also be seen that the improvement of the skin lesions is recorded in detail in the figure. It can be seen from the above that the external pharmaceutical composition does have sufficient repair power and inhibitory power for the degree of itching, wounds and diseases, and it does have an effect that is not available in the prior art compared with the traditional treatment method.

Second embodiment

Please refer to Figures 3 and 4, which are schematic diagrams of the pruritus scale before and after treatment and diagrams of the improvement of skin lesions before and after treatment according to the second embodiment of the present invention. As shown in the figure, the patient in this example has undergone peritoneal dialysis for 6 years and has itching for 2 years. When Mr. Li came to see the doctor for the first time, he was evaluated on the Itching Scale, which is a very serious grade, such as the third As shown in 20181205 on the left side of the picture, its itching seriously affects the patient’s sleep, and there are large areas of skin penetrating sores on the arm. As shown in the leftmost side of picture 4, 20191205, the wound has been unable to close the mouth for a long time except for itching, and it is often necessary Cut the wound with a blade to stop the itching with black blood flowing out. However, after receiving the application of the pharmaceutical composition for external use, the degree of itching was greatly reduced, as shown in the curve in Figure 3, although the curve oscillated but continued to move to the lower right, and the skin wound was also significantly improved and closed. As shown in the comparison of the photos taken in the four time periods of 20191205, 20190102, 20190128 to 20190325 in Figure 4, it can also be seen that the improvement of the skin lesions is recorded in detail in the figure.

The third embodiment

Please refer to Figure 5, which is a diagram showing the improvement of onychomycosis before and after treatment in the third embodiment of the present invention. In addition to treating itching, allergies and repairing wounds, the external pharmaceutical composition can also be used to treat onychomycosis. Thickened and brittle and chipped, it has not been completely cured for 40 years (as shown in 20190505). However, after two months of treatment with the topical pharmaceutical composition, the yellowing and thickening of the nails have been significantly improved, and the nails have been chipped. The nails have also been significantly improved, as shown by the comparison of the photos taken in the 4 time periods from 20190505 to 20190714.

In summary, through the external pharmaceutical composition provided by the present invention and the preparation method thereof, as long as the external pharmaceutical composition is applied to the affected part, the wound can be repaired and the effect of relieving itching and desensitization can be achieved, and because it is pure It is made of natural Kampo herbal ingredients, so it is not as good as western medicine, and may cause damage to the patient's body, so it can be more assured in medicine. In addition, although the ingredients used in the present invention are medicinal materials that will be used in Chinese medicine, the present invention focuses more on the composition ratio of these medicinal materials and the functions and uses they can achieve. Moreover, under such a composition ratio, the present invention The efficacy of the external pharmaceutical composition provided by the invention is the best, and it combines the components of traditional Chinese medicine (medicinal materials) with western auxiliary components (evening primrose oil) and presents them in different ways (lotions, creams, Essential oils, ointments, etc.), and then make products that combine Chinese and Western medicine, which are completely different from traditional Western medicine compound treatments, and their efficacy is greatly enhanced, demonstrating the practicability and innovation of the present invention.

However, the above are only the preferred embodiments of the present invention, and are not used to limit the scope of implementation of the present invention; therefore, equal changes and modifications made without departing from the spirit and scope of the present invention should be covered in Within the scope of the patent of the present invention.

Figure 1 is a schematic diagram of the pruritus scale before and after treatment in the first embodiment of the present invention. Figure 2 is a diagram showing the improvement of skin lesions before and after treatment in the first embodiment of the present invention. Figure 3 is a schematic diagram of the pruritus scale before and after treatment in the second embodiment of the present invention. Figure 4 is a diagram showing the improvement of skin lesions before and after treatment in the second embodiment of the present invention. Figure 5 is a diagram showing the improvement of onychomycosis before and after treatment in the third embodiment of the present invention.

Claims (9)

An application for preparing a pharmaceutical composition for external use to treat itching or allergic symptoms, which is characterized in: The pharmaceutical composition for external use contains Smilax glabra, Nepeta, Parsnip, Kochia scoparia, White fresh peel, Phellodendron amurense, Ligusticum chuanxiong, Angelica, Polygonum multiflorum, Angelica dahurica, Stemona, Sophora flavescens, Bletilla striata and evening primrose oil. As described in item 1 of the scope of the patent application, among them, Smilax glabra is 13 parts by weight, Nepeta is 10 parts by weight, windproof is 5 parts by weight, Kochia scoparia is 5 parts by weight, white Fresh peel is 5 parts by weight, Phellodendron is 5 parts by weight, Chuanxiong is 5 parts by weight, Angelica is 5 parts by weight, Polygonum is 5 parts by weight, Angelica dahurica is 5 parts by weight, 100 The part system is 5 parts by weight, the Sophora flavescens system is 5 parts by weight, and the Bletilla striata system is 5 parts by weight. The use according to item 2 of the scope of patent application, wherein the application mode of the external pharmaceutical composition is selected from one or a combination of the following groups: essential oils, emulsions, creams, solutions, suspensions or ointments. As described in item 3 of the scope of patent application, wherein, itching or allergic symptoms refer to exfoliation (excoriations), lichen simplex (lichen simplex), and pruritus nodularis (pruritus nodularis) caused by uremic pruritus , Keratotic papules (keratotic papules) follicular hyperkeratosis (follicular hyperkeratosis) and acquired perforating dermatosis (APD) or onychomycosis. A method for preparing a pharmaceutical composition for external use for the treatment of itching or allergic symptoms, the steps of which include: Take 13 parts by weight of Smilax glabra, 10 parts by weight of Nepeta, 5 parts by weight of parsnips, 5 parts by weight of Kochia scoparia, 5 parts by weight of white fresh peel, 5 parts by weight of Phellodendron chinense, 5 parts by weight Parts by weight of Ligusticum chuanxiong, 5 parts by weight of Angelica, 5 parts by weight of Polygonum multiflorum, 5 parts by weight of Angelica dahurica, 5 parts by weight of Stemona, 5 parts by weight of Sophora flavescens, and 5 parts by weight of Bletilla striata; After adding the above ingredients to the evening primrose oil, heat it to boil and keep it at 90~100 degrees for 2 hours; and After the oil is extracted and the impurities are filtered, the pharmaceutical composition for external use can be obtained. The preparation method described in item 5 of the scope of patent application, wherein the volume of the evening primrose oil added is 1100 ml. According to the preparation method described in item 6 of the scope of patent application, the external pharmaceutical composition is formulated by adding 300 grams of refined shea butter and 140 grams of refined beeswax to form the external pharmaceutical composition in ointment form Things. The preparation method as described in item 6 of the scope of patent application, wherein the pharmaceutical composition for external use is further added with refined shea butter and olive emulsified wax, and the weight ratio of refined shea butter to olive emulsified wax is 15% 4. After heating to dissolve, add pure water, and the volume ratio of the external pharmaceutical composition to pure water is 10 to 31, and continuous stirring can form the external pharmaceutical composition of cream type. The preparation method described in item 6 of the scope of patent application, wherein the external pharmaceutical composition is further added with refined shea butter and olive emulsified wax, and the weight ratio of refined shea butter to olive emulsified wax is 5 parts 2. After heating to dissolve, add pure water, and the volume ratio of the external pharmaceutical composition to pure water is 5 to 19. Continuous stirring can form the external pharmaceutical composition of emulsion type.

Images